Marinomed Biotech AG (STU:93Z) GF Score : 31/100 (As of Jun. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Marinomed Biotech AG GF Score?

Marinomed Biotech AG has the GF Score of 31, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 2/10
3. Growth Rank : 3/10
4. GF Value Rank : 2/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Marinomed Biotech AG might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Marinomed Biotech AG's GF Score

For the Biotechnology subindustry, Marinomed Biotech AG's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marinomed Biotech AG's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's GF Score distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's GF Score falls into.

Marinomed Biotech AG (STU:93Z) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Marinomed Biotech AG GF Score Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (STU:93Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (STU:93Z) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

MARI:Austria

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (STU:93Z) Headlines

No Headlines